Clinical relevance of a degree of extracapsular extension in a sentinel lymph node in breast cancer patients: a single-centre study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
26 04 2021
26 04 2021
Historique:
received:
24
11
2020
accepted:
07
04
2021
entrez:
27
4
2021
pubmed:
28
4
2021
medline:
11
11
2021
Statut:
epublish
Résumé
In some breast cancer (BC) patients, an examination of lymph nodes dissected during sentinel lymph node biopsy (SLNB) demonstrates a presence of metastatic lesions and extracapsular extension (ECE) in a SLN. This study aimed to evaluate clinical relevance of ECE in BC patients. This is a retrospective analysis of 891 patients with cancer metastases to SLN, referred to supplementary axillary lymph node dissection (ALND), hospitalized between Jan 2007 and Dec 2017. Clinical and epidemiological data was evaluated. Long-term treatment outcomes were analysed. In 433 (48.6%) patients, cancer metastases were limited to the SLN (group I), in 61 (6.8%) patients the SLN capsule was exceeded focally (≤ 1 mm-group II). In 397 (44.6%) patients, a more extensive ECE was found (> 1 mm-group III). Metastases to non-sentinel lymph nodes (nSLNs) were diagnosed in 27.0% patients from group I, 44.3% patients from group II and in 49.6% patients from group III. No statistically significant differences were observed in long-term treatment outcomes for compared groups. The presence of ECE is accompanied by a higher stage of metastatic lesions in the lymphatic system. The differences in this respect were statistically significant, when compared to the group of ECE(-) patients. ECE, regardless of its extent, did not impact the long-term treatment results. ECE remains an indication for supplementary ALND and for other equivalent cancer treatment procedures, regardless of ECE size.
Identifiants
pubmed: 33903665
doi: 10.1038/s41598-021-88351-z
pii: 10.1038/s41598-021-88351-z
pmc: PMC8076211
doi:
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
8982Références
J Clin Oncol. 2000 Aug;18(15):2817-27
pubmed: 10920129
Ann Surg Oncol. 2015 Oct;22(10):3397-401
pubmed: 26215196
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Ann Oncol. 2008 Aug;19(8):1393-1401
pubmed: 18385202
Arch Med Sci. 2017 Oct;13(6):1399-1407
pubmed: 29181071
Ann Oncol. 2017 Aug 1;28(8):1700-1712
pubmed: 28838210
Breast Cancer Res Treat. 2013 Feb;137(3):783-95
pubmed: 23292085
Ann Surg Oncol. 2005 Mar;12(3):246-53
pubmed: 15827817
Surgery. 2000 Aug;128(2):139-44
pubmed: 10922983
Neoplasma. 2014;61(3):299-304
pubmed: 24824931
Clin Breast Cancer. 2016 Jun;16(3):e65-8
pubmed: 26993215
Eur J Surg Oncol. 2016 Jul;42(7):919-25
pubmed: 27005805
Arch Pathol Lab Med. 2015 Oct;139(10):1288-94
pubmed: 25768237
Ann Surg Oncol. 2014 Sep;21(9):2897-903
pubmed: 24777858
JAMA Surg. 2015 Dec;150(12):1141-8
pubmed: 26331347
J Clin Oncol. 2009 Jun 10;27(17):2800-8
pubmed: 19349546
Int J Clin Oncol. 2013 Aug;18(4):607-13
pubmed: 22763660
Ann Surg Oncol. 2015 Jul;22(7):2365-71
pubmed: 25476029
Breast J. 2018 Jul;24(4):480-486
pubmed: 29265572
Neoplasma. 2018 Mar 14;65(3):449-454
pubmed: 29788732